Unique ID issued by UMIN | UMIN000054077 |
---|---|
Receipt number | R000061751 |
Scientific Title | A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients |
Date of disclosure of the study information | 2024/04/05 |
Last modified on | 2024/04/05 23:43:50 |
A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients
A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients
A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients
A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients
Japan |
Breast cancer
Breast surgery | Radiology |
Malignancy
NO
To confirm that ultra-short-term irradiation after breast-conserving surgery is safe and effective in Japanese patients.
Safety,Efficacy
Adverse events at 1, 3, and 6 months after the start of radiation therapy
Observational
20 | years-old | <= |
Not applicable |
Female
Patients must be at least 20 years old at the time of consent (no upper age limit).
Patients scheduled for postoperative irradiation as breast-conserving therapy.
Patients who have been thoroughly informed about their participation in this study and have provided written consent of their own free will based on adequate understanding.
Patients with infections that require systemic treatment.
Pregnant, possibly pregnant, or lactating patients.
Patients who have previously received chest radiation therapy.
Patients are scheduled for concurrent chemotherapy.
Patients with diabetes mellitus who are being treated with continuous insulin injections or are poorly controlled.
Patients diagnosed with interstitial pneumonia, pulmonary fibrosis, or severe emphysema.
Patients receive continuous systemic administration (oral or intravenous) of steroids.
Patients receiving immunosuppressive agents for active collagen disease
Patients with severe cardiac disease or heart failure.
Patients who are deemed ineligible for participation in this study by the principal investigator or principal investigator-designated physicians.
30
1st name | Noriyuki |
Middle name | |
Last name | Okonogi |
Juntendo University
Department of Radiation Oncology
113-8421
2-1-1 Hongo, Bunkyo-ku, Tokyo
03-5802-1230
n.okonogi.rd@juntendo.ac.jp
1st name | Noriyuki |
Middle name | |
Last name | Okonogi |
Juntendo University
Department of Radiation Oncology
113-8421
2-1-1 Hongo, Bunkyo-ku, Tokyo
03-5802-1230
n.okonogi.rd@juntendo.ac.jp
Juntendo University
None
Other
Medical Research Ethics Committee, Juntendo University
Hongo, Bunkyo-ku, Tokyo 1-3
03-3813-3111
n.okonogi.rd@juntendo.ac.jp
NO
2024 | Year | 04 | Month | 05 | Day |
Unpublished
Enrolling by invitation
2024 | Year | 02 | Month | 19 | Day |
2024 | Year | 03 | Month | 29 | Day |
2024 | Year | 05 | Month | 01 | Day |
2025 | Year | 10 | Month | 31 | Day |
After obtaining consent, radiotherapy will be administered according to the regulations, and adverse events will be evaluated at 1, 3, and 6 months after the start of treatment.
2024 | Year | 04 | Month | 05 | Day |
2024 | Year | 04 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061751
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |